The prevalence and prognostic value of KRAS co ‐mutation subtypes in Chinese advanced non‐small cell lung cancer patients

ConclusionOur study revealed that concurrent genomic alterations can further stratify KRAS ‐mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. The KPL is a novel and less responsive subtype amongKRAS‐mutated NSCLC, and further investigation of effective treatment for this subtype is warranted.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research